SynthesisFrontiers in medicine2025
Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) combined with hyperuricemia (HUA) constitutes a pathological state of vicious cycle, where diabetic microvascular complications affect the kidneys and interact with persistent hyperuricemia. This condition significantly accelerates the progression of renal failure and increases all-cause mortality. Objective: This study aims to systematically evaluate the clinical efficacy and safety of febuxostat in treating patients with DKD and HUA via a meta-analysis, thereby providing evidence-based guidance for optimizing clinical medication. Methods: Following the PICOS principle, we systematically searched for randomized controlled trials (RCTs) on febuxostat for treating DKD combined with HUA, covering the period from the establishment of each database to June 26, 2025. Studies meeting the inclusion criteria were selected, and a meta-analysis was performed using Review Manager 5.4 software. Results: A total of 17 RCTs were included, involving 1,300 patients (treatment group n=647, control group Conclusion: This meta-analysis indicates that febuxostat, when used to treat patients with DKD and HUA, can significantly enhance overall clinical effectiveness and effectively improve key renal function indicators-including SUA, UACR, Scr, BUN, and eGFR. The results of this study showed that when febuxostat is used to treat patients with diabetic nephropathy complicated by hyperuricemia, it achieves a higher overall clinical response rate. It can significantly reduce the levels of SUA, UACR, Scr, and BUN in patients, while improving the eGFR. Additionally, the incidence of adverse reactions associated with febuxostat is lower, suggesting that this drug exhibits favorable clinical safety. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.